Rabbit Anti-Human Lyve-1

Slide this table

Cat-Nr.102-PA50AG
Size50 µg
Price210 €
CategoryPolyclonal Antibody
Clone Nr.Rabbit IG
Species ReactivityHuman
Formulationlyophilized
BufferPBS
ReconstitutionCentrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.
Stability and StorageThe lyophilized antibody is stable at room temperature for up to 1 month. The reconstituted antibody is stable for at least two weeks at 2-8 °C. Frozen aliquots are stable for at least 6 months when stored at -20 °C.
PreparationProduced from sera of rabbits immunized with highly pure recombinant human soluble LYVE-1 produced in insect cells. The recombinant soluble LYVE-1consists of amino acid 24 (Ser) to 232 (Gly) and is fused to a C-terminal His-tag (6xHis). LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE-1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 molecule co-localizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.
AntigenRecombinant human LYVE-1 (RT #S01-028)
ApplicationWB, IHC (P, F), IF
SynonymsLYVE1; HAR; XLKD1; LYVE-1; CRSBP-1
DescriptionLYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE-1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.
Uniprot IDQ9Y5Y7
Protein RefSeqNP_006682
mRNA RefSeqNM_006691

Figures


Protocol

a) For IF with LECPDF download
b) For FACSPDF download

 


Reference

  1. Engineering Blood and Lymphatic Microvascular Networks in Fibrin Matrices. L. Knezevic et al., Front Bioeng Biotechnol. 2017; 5: 25.
  2. TGFβ counteracts LYVE-1-mediated induction of lymphangiogenesis by small hyaluronan oligosaccharides. Bauer J. et al., J Mol Med (Berl). 2018 Feb;96(2):199-209.
  3. ELM: A New, Simple, and Economic Assay to Measure Motility of Lymphatic Endothelial Cells. F. Torri et al., Res Biol. 2017 Mar 1; 15(1): 39–44.
  4. Fetal liver endothelium regulates the seeding of tissue-resident macrophages. Rantakari P. et al., Nature. 2016 Oct 20;538(7625):392-396.
  5. Orbital angiogenesis and lymphangiogenesis in thyroid eye disease: an analysis of vascular growth factors with clinical correlation. L. L. Wong et al., Ophthalmology. 2 16 Sep; 123(9): 2028–2036.    
  6. Morphological and Molecular Characterization of Human Dermal Lymphatic Collectors. V. Hasselhof et al., PLoS One. 2016; 11(10): e0164964.
  7. Understanding Lymphatic Drainage Pathways of the Ovaries to Predict Sites for Sentinel Nodes in Ovarian Cancer. M. Kleppe et al., Int J Gynecol Cancer. 2015 Oct; 25(8): 1405–1414.
  8. The endothelial protein PLVAP in lymphatics controls the entry of lymphocytes and antigens into lymph nodes. Rantakari P. et al., Nat Immunol. 2015 Apr;16(4):386-96.
  9. TGF-β1-induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR7/CCL21-mediated chemotaxis.    M-F Pang et al., Oncogene. 2016 Feb 11; 35(6): 748–760.
  10. Generation of pure lymphatic endothelial cells from human pluripotent stem cells and their therapeutic effects on wound repair. Shin-Jeong Lee et al., Sci Rep. 2015; 5: 11019.
  11. Adhesion of Pancreatic Cancer Cells in a Liver-Microvasculature Mimicking Coculture Correlates with Their Propensity to Form Liver-Specific Metastasis In Vivo. M. Mahfuz Chowdhury et al., Biomed Res Int. 2014; 2014: 241571.
  12. Arterial wall lymphangiogenesis is increased in the human iliac atherosclerotic arteries: involvement of CCR7 receptor. Grzegorek I. et al., Lymphat Res Biol. 2014 Dec;12(4):222-31.
  13. Lymphangiogenesis and angiogenesis during human fetal pancreas development. M. S. Roost et al., Vasc Cell. 2014; 6: 22.
  14. Lack of Lymphatics and Lymph Node–Mediated Immunity in Choroidal Neovascularization. S. Nakao et al., Invest Ophthalmol Vis Sci. 2013 Jun; 54(6): 3830–3836.
  15. Plasticity of Blood- and Lymphatic Endothelial Cells and Marker Identification. J. Keuschnigg et al., PLoS One. 2013; 8(9): e74293.    
  16. High density of peritumoral lymphatic vessels measured by D2-40/podoplanin and LYVE-1 expression in gastric cancer patients: an excellent prognostic indicator or a false friend? J. Rudno-Rudzinska et al., Gastric Cancer. 2013; 16(4): 513–520.            
  17. Increased lymphatic vessel density and lymphangiogenesis in inflammatory bowel disease. Rahier JF et al., Aliment Pharmacol Ther. 2011 Sep;34(5):533-43.
  18. An exquisite cross-control mechanism among endothelial cell fate regulators directs the plasticity and heterogeneity of lymphatic endothelial cells. J. Kang et al., Blood. 2010 Jul 8; 116(1): 140–150.
  19. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Smith NR et al., Clin Cancer Res. 2010 Jul 15;16(14):3548-61.
  20. Thymus cell antigen 1 (Thy1, CD90) is expressed by lymphatic vessels and mediates cell adhesion to lymphatic endothelium. G. Jurisic et al., Exp Cell Res. 2010 Oct 15; 316(17): 2982–2992.
  21. Exercise-induced decline in the density of LYVE-1-positive lymphatic vessels in human skeletal muscle. Gehlert S. et al., Lymphat Res Biol. 2010 Sep;8(3):165-73.
  22. Regeneration of autotransplanted avascular lymph nodes in the rat is improved by platelet-rich plasma. Hadamitzky C et al., J Vasc Res. 2009;46(5):389-96.
  23. Endosialin (Tem1) Is a Marker of Tumor-Associated Myofibroblasts and Tumor Vessel-Associated Mural Cells. S. Christian et al., Am J Pathol. 2008 Feb; 172(2): 486–494.
  24. Altered regulation of Prox1-gene-expression in liver tumors. J. Dudas etal., BMC Cancer. 2008; 8: 92.
  25. Chemokine CCL2 facilitates ICAM-1-mediated interactions of cancer cells and lymphatic endothelial cells in sentinel lymph nodes. Kawai Y. et al., Cancer Sci. 2009 Mar;100(3):419-28.
  26. The lymphatic ring assay: a 3D-culture model of lymphangiogenesis. F. Bruyère et al., Protocol Exchange (2008)
  27. Jugular lymphatic maldevelopment in Turner syndrome and trisomy 21: different anomalies leading to nuchal edema. Bekker MN et al., Reprod Sci. 2008 Apr;15(3):295-304.

All prices plus VAT + possible delivery charges